Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:e676
doi: 10.1161/CIRCULATIONAHA.108.780817
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elkayam, U.
Right arrow Articles by Mehra, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Elkayam, U.
Right arrow Articles by Mehra, A.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology

(Circulation. 2008;118:e676.)
© 2008 American Heart Association, Inc.


Correspondence

Response to Letter Regarding Article, "Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action"

Uri Elkayam, MD; Tien M.H. Ng, PharmD; Parta Hatamizadeh, MD; Munir Janmohamed, MD; Anilkumar Mehra, MD

Division of Cardiology, University of Southern California, Keck School of Medicine, Los Angeles, Calif

Drs Lema and Canessa point out the important intersubject variability of plasma levels of dopamine, which has been shown in normal volunteers. These differences may also be related to the interpatient variability in dopamine dose producing the largest effect on renal blood flow. In our study,1 5 patients demonstrated a maximal increase in renal blood flow at a dopamine dose ≤3 µg · kg–1 · min–1, whereas 3 patients demonstrated a maximal increase in renal blood flow at a dose of 5 µg · kg–1 · min–1, and 5 patients demonstrated a maximal increase in renal blood flow at dose of 10 µg · kg–1 · min–1. The majority of the patients, therefore, exhibited the greatest response to dopamine at doses greater than the traditional "renal dose."


*    Acknowledgments
 
Disclosures

None.


*    Reference
up arrowTop
*Reference
 
1. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation. 2008; 117: 200–205.[Abstract/Free Full Text]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elkayam, U.
Right arrow Articles by Mehra, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Elkayam, U.
Right arrow Articles by Mehra, A.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology